Forum Posts

• July 28, 2021 3:12 AM PDT

  in the topic Cancer Biomarkers Market Share, Growth Analysis by 2030 in the forum News and Announcements

  Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2021–2030.”

  The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

  • A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
  • An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
  • An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
  • Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
  • A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
  • A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.
  • A discussion on various steps involved in development operations of companion diagnostics
  • A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products.

  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  Request for Customization:

  https://www.rootsanalysis.com/reports/253/request-customization.html

  Type of test

  • Laboratory Developed Tests (LDTs)
  • Companion Diagnostic Tests (CDx)

  Type of disease indication

  • Breast cancer
  • Blood cancer
  • Colon / Colorectal cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer

  Type of cancer biomarker

  • TMB
  • MSI / MMR
  • TILs

  Type of analytical technique

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Others

  Key geographical regions

  • North America
  • Europe
  • Japan
  • China
  • Australia

  Key companies covered in the report

  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology

  Enquiry before Purchasing:

  https://www.rootsanalysis.com/reports/253/request-sample.html   

  Please Visit Our Upcoming Reports

  Gonorrhea: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  Non-Viral Drug Delivery Systems (Focus on Intracellular Technologies and Intracellular Biologics) Market

  Lactose Intolerance: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  Helicobacter pylori (H. pylori) Infection: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  Cold Chain Logistics Market, Industry Trends and Global Forecasts, 2021-2030

  About Roots Analysis

  Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

  Contact Information

  Roots Analysis Private Limited

  Gaurav Chaudhary

  +1 (415) 800 3415

  Gaurav.Chaudhary@rootsanalysis.com

• July 26, 2021 4:53 AM PDT

  in the topic Cell Therapy Manufacturing Market Share by 2021-2030 in the forum News and Announcements

  Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market, 2021-2030.” 

  The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:

  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019.
  • An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019.
  • Informed estimates of the annual commercial and clinical demand for cell therapies, in terms of number of cells produced and area dedicated to manufacturing.
  • An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
  • A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • An elaborate discussion on the role of automation technologies in improving current manufacturing methods.
  • A discussion on cell therapy manufacturing regulations across various geographies, including North America, Europe, and Asia Pacific.
  • Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework.

  Get Detailed Market Analysis:

  https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  Type of therapy

  • T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
  • Dendritic cell therapies
  • Tumor cell therapies
  • NK cell therapies
  • Stem cell therapies

  Source of cells

  • Autologous
  • Allogeneic

  Scale of operation

  • Clinical
  • Commercial

  Purpose of manufacturing

  • Contract manufacturing
  • In-house manufacturing

  Key geographical regions

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

  Key companies covered in the report

  • BioNTech Innovative Manufacturing Services
  • Cell Therapies
  • Cell and Gene Therapy Catapult
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Centre for Cell Manufacturing Ireland, National University of Ireland
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania
  • Cognate BioServices
  • FUJIFILM
  • Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
  • Hitachi Chemical
  • KBI Biopharma
  • Laboratory for Cell and Gene Medicine, Stanford University
  • Lonza
  • MaSTherCell
  • MEDINET
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Newcastle Cellular Therapies Facility, Newcastle University
  • Nikon CeLL innovation
  • Rayne Cell Therapy Suite, King’s College London
  • Roslin Cell Therapies
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
  • Sydney Cell and Gene Therapy
  • WuXi Advanced Therapies

  Get an Exclusive PDF Sample:  https://www.rootsanalysis.com/reports/285/request-sample.html

  Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Overview
  5. Regulatory Landscape
  6. Roadmaps for Overcoming Existing Challenges
  7. Automation Technologies for Cell Therapy Manufacturing
  8. Profiles: Industry Players
  9. Profiles: Non-Industry Players
  10. Role of Non-Profit Organizations
  11. Partnerships
  12. Facility Expansions
  13. Capacity Analysis
  14. Demand Analysis
  15. Cost Price Analysis
  16. Make Versus Buy Decision Making Framework
  17. Market Sizing and Opportunity Analysis
  18. Key Insights
  19. SWOT Analysis
  20. Conclusion
  21. Survey Analysis
  22. Interview Transcripts
  23. Appendix 1: Tabulated Data
  24. Appendix 2: List of Companies and Organizations

  Request for Customization:

  https://www.rootsanalysis.com/reports/285/request-customization.html    

  Also Visit Our Latest Publication:

  Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

  CAR-T Cell Therapies Market

  Patient Recruitment and Retention Services Market

  mRNA Therapeutics and Vaccines Market

  T-Cell (CAR-T, TCR, and TIL) Therapies Market

   

• July 22, 2021 5:14 AM PDT

  in the topic Biopharmaceutical Contract Manufacturing Market 2021 in the forum News and Announcements

  Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.” 

  The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
  • An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

  Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html     ;

  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  Commonly Outsourced Business Operations

  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)

  Types of Expression System

  • Mammalian
  • Microbial
  • Others

  Company Size

  • Small
  • Mid-Sized
  • Large and Very Large

  Scale of Operation

  • Preclinical
  • Clinical
  • Commercial

  Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

  The report also features detailed transcripts of discussions held with the following experts:

  • Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • Christian Bailly, Director of CDMO, Pierre Fabre
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • Kevin Daley, Director Pharmaceuticals, Novasep
  • Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • Nicolas Grandchamp, R&D Leader, GEG Tech
  • Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • Sebastian Schuck, Head of Business Development, Wacker Biotech
  • Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
  • Tim Oldham, Chief Executive Officer, Cell Therapies

  Key companies covered in the report

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

  For more information, please click on the following link:

  https://www.rootsanalysis.com/reports/250/request-sample.html    

  Also Visit Our Latest Publication:

  Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

  CAR-T Cell Therapies Market

  Patient Recruitment and Retention Services Market

  mRNA Therapeutics and Vaccines Market

  T-Cell (CAR-T, TCR, and TIL) Therapies Market

• July 21, 2021 3:59 AM PDT

  in the topic Antibody Contract Manufacturing Market by 2030 in the forum News and Announcements

  Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

  Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production.

  Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

  The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies.
  • A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength and service strength.
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October).
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain.
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.

  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  Ask for Customization @ https://www.rootsanalysis.com/reports/295/request-customization.html

  Type of Antibodies

  • Monoclonal Antibodies
  • Bispecific Antibodies
  • ADCs
  • Others

  Company Size

  • Small
  • Mid-sized
  • Large / Very Large

  Scale of Operation

  • Preclinical / Clinical
  • Commercial

  Type of expression system used

  • Mammalian
  • Microbial

  Key geographical regions

  • North America
  • Europe
  • Asia and RoW

  Transcripts of interviews held with the following senior level representatives of stakeholder companies:

  • Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
  • David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
  • Claire Otjes (Marketing Manager, Batavia Biosciences)

  Market Key Players:

  • AGC Biologics
  • Aldevron
  • AMRI
  • Boehringer Ingelheim BioXcellence
  • Emergent BioSolutions
  • Eurofins CDMO
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • Nitto Avecia Pharma Services
  • Novasep
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific

  For more information, please click on the following link:

  https://www.rootsanalysis.com/reports/295/request-sample.html    

  Also Visit Our Latest Publication:

  Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

  CAR-T Cell Therapies Market

  Patient Recruitment and Retention Services Market

  mRNA Therapeutics and Vaccines Market

  T-Cell (CAR-T, TCR, and TIL) Therapies Market

• July 20, 2021 4:49 AM PDT

  in the topic Target Protein Degradation Market by 2030 in the forum News and Announcements

  The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.

  Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

  The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:

  Type of payment of licensing agreements

  • Upfront payments
  • Milestone payments

  Type of protein degrader

  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

  Therapeutic area

  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

  Route of administration 

  • Oral
  • Intravenous
  • Other routes

  Key geographical region

  • North America
  • Europe
  • Asia-Pacific

  Get Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

  Key Inclusions

  • A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
  • Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.
  • Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
  • An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.

  Key Players

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

  Get Customized Report: https://www.rootsanalysis.com/reports/289/request-customization.html

  Also Visit Our Latest Publication

  HER2 Targeting Therapies Market

  Solar Tracker Market

  North America Telecom Power Systems Market

  Nephrotic Syndrome Market

  Erythropoietic Protoporphyria Market